Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial

NCT06649331 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06649331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
October 21, 2024
Completion date
September 30, 2027
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, her2-negative breast cancer, metastatic breast cancer, triple negative breast cancer (tnbc)